Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT)

CONCLUSION: The 5-year benefit-risk profile for upadacitinib in RA remains favorable.PMID:38621793 | DOI:10.3899/jrheum.2023-1062

Source: Journal of Rheumatology - April 15, 2024 Category: Rheumatology Authors: Gerd R Burmester Filip Van den Bosch John Tesser Anna Shmagel Yanxi Liu Nasser Khan Heidi S Camp Alan Kivitz Source Type: research